Ian Spendlove

Contact

• workAcademic Clinical Oncology
  Nottingham City Hospital
  Hucknall Road
  Nottingham
  NG5 1PB
  UK
• work0115 8231857
• fax0115
• ian.spendlove@nottingham.ac.uk
• http://www.nottingham.ac.uk/oncology/Welcome.html

Research Summary

the current research funded by the Cancer Research UK, Pancreatic Cancer Fund and Lewis Charitable trust is aimed at generating direct killing antibodies against tumour glycolipids aberrantly… read more

Selected Publications

• AITHAL, G.P., THOMAS, J. A., KAYE, P.V., LAWSON, A., RYDER, S.D., SPENDLOVE, I.S., AUSTIN, A.S., FREEMAN, J.G., MORGAN, L, and WEBBER, D.M.J., 2008. A randomized, double blind, placebo controlled trial of one year of pioglitazone in non-diabetic subjects with nonalcoholic steatohepatitis Gastroenterology. 135, 1176-1184
• SPENDLOVE, I., AL-ATTAR, A., WATHERSTONE, O., WEBB, T. M., ELLIS, E. O., LONGMORE G. D. and SHARP T. V., 2008. Differential subcellular localisation of the tumour suppressor protein LIMD1 in breast cancer correlates with patient survival.: Tumour suppressor protein LIMD1 in breast cancer International Journal of Cancer. 123, 2247-2253
• DUNCAN, TIMOTHY J, AL-ATTAR, AHMAD, ROLLAND, PHIL, SCOTT, IAN V, DEEN, SUHA, LIU, DAVID T Y, SPENDLOVE, IAN and DURRANT, LINDY G, 2008. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clinical Cancer Research. 14(10), 3030-5
• ULLENHAG, G J, SPENDLOVE, I, WATSON, N F S, KALLMEYER, C, PRITCHARD-JONES, K and DURRANT, L G, 2008. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clinical Immunology. 128(2), 148-54

• View all publications

Current Research

the current research funded by the Cancer Research UK, Pancreatic Cancer Fund and Lewis Charitable trust is aimed at generating direct killing antibodies against tumour glycolipids aberrantly expressed by tumours. These antibodies have unique capability in causing cell killing by unknown mechanisms. The aim is to characterise these antibodies and their targets and establish the role of the antigens in cell killing.

• DURRANT LG, NOBLE P and SPENDLOVE I, 2012. Immunology In The Clinic Review Series; Focus On Cancer: Glycolipids As Targets For Tumour Immunotherapy. Clinical And Experimental Immunology. 167(2), 206-15
• POPPLE, A, DURRANT, LG., SPENDLOVE, I., ROLLAND, P., SCOTT, I., DEEN, S. and RAMAGE, JM., 2012. The Chemokine CXCL12 is an independent predictor of poor survival in ovarian cancer. British Journal of Cancer: BJC. 106, 1306-1313
• STEPHANIE FOAN, ANDREW M JACKSON, IAN SPENDLOVE, UWE AICKELIN, 2011. Simulating the Dynamics of T Cell Subsets Throughout the Lifetime. In: PIETRO LIO, GIUSEPPE NICOSIA, THOMAS STIBOR, ed., LNCS Artificial Immune Systems: Proceedings of 10th International Conference on Artificial Immune Systems (ICARIS2011) Vol:6825. Springer. 71-76
• BAXENDALE A, VAN HOOFF P, DURRANT LG, SPENDLOVE I, HOWDLE SM, WOODS HM, WHITAKER MJ, DAVIES OR, NAYLOR A, LEWIS AL and ILLUM L, 2011. Single Shot Tetanus Vaccine Manufactured By A Supercritical Fluid Encapsulation Technology. International Journal Of Pharmaceutics. 413(1-2), 147-54
• PUDNEY VA, METHERINGHAM RL, GUNN B, SPENDLOVE I, RAMAGE JM and DURRANT LG, 2010. Dna Vaccination With T-Cell Epitopes Encoded Within Ab Molecules Induces High-Avidity Anti-Tumor Cd8+ T Cells. European Journal Of Immunology. 40(3), 899-910
• DURRANT LG, PUDNEY V, SPENDLOVE I and METHERINGHAM RL, 2010. Vaccines As Early Therapeutic Interventions For Cancer Therapy: Neutralising The Immunosuppressive Tumour Environment And Increasing T Cell Avidity May Lead To Improved Responses. Expert Opinion On Biological Therapy. 10(5), 735-48
• DUNCAN TJ, AL-ATTAR A, ROLLAND P, HARPER S, SPENDLOVE I and DURRANT LG, 2010. Cytoplasmic P27 Expression Is An Independent Prognostic Factor In Ovarian Cancer. International Journal Of Gynecological Pathology : Official Journal Of The International Society Of Gynecological Pathologists. 29(1), 8-18
• DUNCAN, TIMOTHY J, AL-ATTAR, AHMAD, ROLLAND, PHIL, SCOTT, IAN V, DEEN, SUHA, LIU, DAVID T Y, SPENDLOVE, IAN and DURRANT, LINDY G, 2008. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clinical Cancer Research. 14(10), 3030-5
• ULLENHAG, G J, SPENDLOVE, I, WATSON, N F S, KALLMEYER, C, PRITCHARD-JONES, K and DURRANT, L G, 2008. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clinical Immunology. 128(2), 148-54
• AITHAL, G.P., THOMAS, J. A., KAYE, P.V., LAWSON, A., RYDER, S.D., SPENDLOVE, I.S., AUSTIN, A.S., FREEMAN, J.G., MORGAN, L, and WEBBER, D.M.J., 2008. A randomized, double blind, placebo controlled trial of one year of pioglitazone in non-diabetic subjects with nonalcoholic steatohepatitis Gastroenterology. 135, 1176-1184
• SPENDLOVE, I., AL-ATTAR, A., WATHERSTONE, O., WEBB, T. M., ELLIS, E. O., LONGMORE G. D. and SHARP T. V., 2008. Differential subcellular localisation of the tumour suppressor protein LIMD1 in breast cancer correlates with patient survival.: Tumour suppressor protein LIMD1 in breast cancer International Journal of Cancer. 123, 2247-2253
• ROLLAND, P., MADJD, Z., DURRANT, L., ELLIS, I.O., LAYFIELD, R. and SPENDLOVE, I., 2007. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease Endocrine-Related Cancer. 14(1), 73-80
• ROLLAND, PHIL, SPENDLOVE, IAN, MADJID, ZAHRA, RAKHA, EMAD A, PATEL, POULAM, ELLIS, IAN O and DURRANT, LINDY, 2007. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. International Journal of Cancer. 120(6), 1311-7
• ABBOTT, R.J.M., SPENDLOVE, I., ROVERSI, P., FITZGIBBON, H., KNOTT, V., TERIETE, P., MCDONNELL, J.M., HANDFORD, P.A. and LEA, S.M., 2007. Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55 Journal of Biological Chemistry. 282(30), 22023-22032
• ROLLAND, P., DEEN, S., SCOTT, I., DURRANT, L. and SPENDLOVE, I., 2007. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer Clinical Cancer Research. 13, 3591-3596
• DUNCAN, T.J., ROLLAND, P, DEEN,S, SCOTT, I. V., LIU, D. T, SPENDLOVE, I and DURRANT, L. G., 2007. Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. Clin Cancer Res.. 13, 4139-45
• CAPASSO, M., DURRANT, L.G., STACEY, M., GORDON, S., RAMAGE, J. and SPENDLOVE, I., 2006. Costimulation via CD55 on human CD4⁺ T Cells mediated by CD97 The Journal of Immunology. 177(2), 1070-1077
• ULLENHAG, G.J., SPENDLOVE, I., WATSON, N.F.S., INDAR, A.A., DUBE, M., ROBINS, R.A., MAXWELL-ARMSTRONG, C., SCHOLEFIELD, J.H. and DURRANT, L.G., 2006. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55 Clinical Cancer Research. 12(24), 7389-7396
• WATSON, N.F.S., SPENDLOVE, I., MADJD, Z., MCGILVRAY, R., GREEN, A.R., ELLIS, I.O., SCHOLEFIELD, J.H. and DURRANT, L.G., 2006. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients International Journal of Cancer. 118(6), 1445-1452
• SPENDLOVE, I., RAMAGE, J.M., BRADLEY, R., HARRIS, C. and DURRANT, L.G., 2006. Complement decay accelerating factor (DAF)/CD55 in cancer Cancer Immunology & Immunotherapy. 55(8), 987-995
• WATSON, N. F. S., RAMAGE, J. M., MADJD, Z., SPENDLOVE, I., ELLIS, I. O., SCHOLEFIELD, J. H. and DURRANT, L. G., 2006. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis International Journal of Cancer. VOL 118(NUMB 1), 6-10
• PRITCHARD-JONES, K., SPENDLOVE, I., WILTON, C., WHELAN, J., WEEDEN, S., LEWIS, I., HALE, J., DOUGLAS, C., PAGONIS, C., CAMPBELL, B., ALVAREZ, P., HALBERT, G. and DURRANT, L.G., 2005. Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma British Journal of Cancer. 92(8), 1358-1365
• MADJD, Z., DURRANT, L.G., PINDER, S.E., ELLIS, I.O., RONAN, J., LEWIS, S., RUSHMERE, N.K. and SPENDLOVE, I., 2005. Do poor-prognosis breast tumours express membrane cofactor proteins (CD46) Cancer Immunology, Immunotherapy. 54(2), 149-156
• MADJD,Z., PARSONS,T., WATSON,N., SPENDLOVE,I., ELLIS,I. and DURRANT,L.G, 2005. High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas Breast Cancer Research. 7(5), R780-R787
• MADJD, Z., SPENDLOVE, I., PINDER, S. E., ELLIS, I. O. and DURRANT, L. G., 2005. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer International Journal of Cancer. VOL 117(NUMB 2), 248-255
• RAMAGE, J.M., METHERINGHAM, R., CONN, A., SPENDLOVE, I., MOSS, R.S., PATTON, D.T., MURRAY, J.C., REES, R.C. and DURRANT, L.G., 2004. Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2 International Journal of Cancer. 110(2), 245-250
• MADJD, Z., DURRANT, L. G., BRADLEY, R., SPENDLOVE, I., ELLIS, I. O. and PINDER, S. E., 2004. Loss of CD55 Is Associated with Aggressive Breast Tumors Clinical Cancer Research. VOL 10(PART 8), 2797-2803
• PARSONS, T., SPENDLOVE, I., NIRULA, R., WRITER, M., CARTER, G., CARR, F. and DURRANT, L. G., 2004. A novel CEA vaccine stimulates T cell proliferation, gIFN secretion and CEA specific CTL responses Vaccine. VOL 22(NUMBER 25-26), 3487-3494
• DURRANT,L.G. and SPENDLOVE,I., 2003. Cancer vaccines entering Phase III clinical trials. Expert Opinion on Emerging Drugs. 8(2), 489-500
• MORGAN, J., SPENDLOVE, I. and DURRANT, L. G., 2002. The role of CD55 in protecting the tumour environment from complement attack Tissue Antigens. VOL 60(PART 3), 213-223
• LI, L., SPENDLOVE, I., MORGAN, J. and DURRANT, L.G., 2001. CD55 is over-expressed in the tumour environment British Journal of Cancer. 84(1), 80-86
• DURRANT, L. G., PARSONS, T., MOSS, R., SPENDLOVE, I., CARTER, G. and CARR, F., 2001. Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses International Journal of Cancer. VOL 92(PART 3), 414-420
• DURRANT, L G and SPENDLOVE, I, 2001. Immunization against tumor cell surface complement-regulatory proteins. Current Opinion in Investigational Drugs. 2(7), 959-66
• SPENDLOVE, I., LI, L., POTTER, V., CHRISTIANSEN, D., LOVELAND, B. E. and DURRANT, L. G., 2000. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions European Journal of Immunology. VOL 30(PART 10), 2944-2953
• DURRANT, L. G., BUCKLEY, D. J., ROBINS, R. A. and SPENDLOVE, I., 2000. 105AD7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses International Journal of Cancer. VOL 85(NUMBER 1), 87-92
• MCELVEEN, J.E., FURTADO, P.B., SMITH, S.J., CLARK, M.R., SPENDLOVE, I., SEWELL, H.F. and SHAKIB, F., 2000. Characterisation of a mouse monoclonal anti-idiotype reactive with a V region sequence commonly used by human immunoglobulins Molecular Pathology. VOL 53(PART 2), 77-82
• SPENDLOVE, I, LI, L, CARMICHAEL, J and DURRANT, L G, 1999. Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Research. 59(10), 2282-6
• DURRANT, L G, BUCKLEY, D J, SPENDLOVE, I and ROBINS, R A, 1997. Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumor T-cell immunity. Hybridoma.. 16(1), 23-6
• DURRANT, L G and SPENDLOVE, I, 1996. Cancer vaccines. QJM (Quarterly Journal of Medicine). 89(9), 645-51
• LOWE, J, MCDERMOTT, H, PIKE, I, SPENDLOVE, I, LANDON, M and MAYER, R J, 1992. alpha B crystallin expression in non-lenticular tissues and selective presence in ubiquitinated inclusion bodies in human disease. Journal of Pathology. 166(1), 61-8
• POLLER, D N, SPENDLOVE, I, BAKER, C, CHURCH, R, ELLIS, I O, PLOWMAN, G D and MAYER, R J, 1992. Production and characterization of a polyclonal antibody to the c-erbB-3 protein: examination of c-erbB-3 protein expression in adenocarcinomas. Journal of Pathology. 168(3), 275-80
• LOWE, J, ERRINGTON, D R, LENNOX, G, PIKE, I, SPENDLOVE, I, LANDON, M and MAYER, R J, 1992. Ballooned neurons in several neurodegenerative diseases and stroke contain alpha B crystallin. Neuropathology and Applied Neurobiology. 18(4), 341-50
• LOWE, J, LANDON, M, PIKE, I, SPENDLOVE, I, MCDERMOTT, H and MAYER, R J, 1990. Dementia with beta-amyloid deposition: involvement of alpha B-crystallin supports two main diseases. Lancet. 336(8713), 515-6